- Home
- USIO vs TPST Comparison
USIO vs TPST Comparison
Compare USIO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | TPST |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3M | 30.9M |
| IPO Year | 1999 | 2012 |
Fundamental Metrics
Financial Performance| Metric | USIO | TPST |
|---|---|---|
| Price | $1.50 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $11.00 |
| AVG Volume (30 Days) | 55.5K | ★ 173.9K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,200,535.00 | $295,000.00 |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $8.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $1.50 |
| 52 Week High | $2.02 | $12.22 |
Technical Indicators
Market Signals| Indicator | USIO | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 69.20 | 45.82 |
| Support Level | $1.36 | $1.57 |
| Resistance Level | $1.58 | $2.48 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 73.48 | 35.19 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.